Insider Selling: Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sells $770,997.89 in Stock

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Xenon Pharmaceuticals Stock Performance

NASDAQ XENE opened at $38.63 on Friday. The firm has a market capitalization of $2.95 billion, a PE ratio of -13.70 and a beta of 1.19. Xenon Pharmaceuticals Inc. has a one year low of $35.53 and a one year high of $50.99. The company has a 50-day simple moving average of $41.85 and a 200-day simple moving average of $40.48.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) EPS for the quarter, beating analysts’ consensus estimates of ($0.82) by $0.01. During the same period last year, the company earned ($0.73) earnings per share. Equities analysts forecast that Xenon Pharmaceuticals Inc. will post -3.1 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on XENE shares. HC Wainwright reiterated a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Thursday, December 12th. Raymond James reaffirmed an “outperform” rating and issued a $50.00 target price on shares of Xenon Pharmaceuticals in a research report on Thursday, October 10th. Royal Bank of Canada reissued an “outperform” rating and set a $55.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, September 3rd. William Blair raised shares of Xenon Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research note on Wednesday, November 13th. Eight analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Xenon Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $56.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC lifted its stake in Xenon Pharmaceuticals by 1,275.5% in the third quarter. Barclays PLC now owns 14,993 shares of the biopharmaceutical company’s stock valued at $590,000 after buying an additional 13,903 shares during the last quarter. Vestcor Inc acquired a new stake in shares of Xenon Pharmaceuticals in the 3rd quarter worth about $327,000. Y Intercept Hong Kong Ltd lifted its position in Xenon Pharmaceuticals by 68.8% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 24,557 shares of the biopharmaceutical company’s stock valued at $967,000 after purchasing an additional 10,007 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Xenon Pharmaceuticals by 0.4% during the third quarter. Wellington Management Group LLP now owns 3,843,447 shares of the biopharmaceutical company’s stock valued at $151,317,000 after buying an additional 15,226 shares during the last quarter. Finally, Two Sigma Advisers LP raised its stake in Xenon Pharmaceuticals by 31.0% during the 3rd quarter. Two Sigma Advisers LP now owns 273,700 shares of the biopharmaceutical company’s stock valued at $10,776,000 after acquiring an additional 64,800 shares in the last quarter. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.